Revenue segments as reported by the company.

Proprietary Products

Contract - Manufactured Products

Eliminations

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Other (income) expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

West Pharmaceutical Services

West Pharmaceutical Services, Inc. manufactures and markets pharmaceuticals, biologics, vaccines and consumer healthcare products. It operates through the following business segments: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers proprietary packaging, containment and drug delivery products, along with analytical lab services, to biologic, generic and pharmaceutical drug customers. The Contract-Manufactured Products segment serves as a fully integrated business, focused on the design, manufacture and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers. The company was founded by Herman O. West on July 27, 1923 and is headquartered in Exton, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

West Pharmaceutical Services reports solid growth and strategic investments

West Pharmaceutical Services showed resilience with 8% organic sales growth in 2022 despite challenges.
2023 guidance includes growth projections, margin expansion, and a share repurchase program.
The company's pricing strategy and investments in high-value products position it for future success.
Despite COVID impacts, West remains focused on growth opportunities and sustainability efforts.

West Pharmaceutical Services reports solid Q1 performance and growth outlook

West Pharmaceutical Services (WST) showcased strong Q1 performance with growth in key market units and ongoing investments in capacity expansion.
Despite challenges such as declining profitability metrics and inflationary pressures, the company remains optimistic about its full-year outlook and growth prospects.
Opportunities lie in sustained growth in Contract Manufacturing, revenue diversification, and a focus on margin expansion to drive future financial success.
Analysts' inquiries highlighted areas for improvement, signaling a proactive approach to addressing challenges and capitalizing on growth opportunities.

West Pharmaceutical Services excels in Q2, eyes growth opportunities

West Pharmaceutical Services reported strong Q2 performance driven by key business units and growth drivers, with a focus on sustainability and capacity investments. Despite challenges like margin expectations and external events, the company remains well-positioned for growth. Opportunities lie in revenue pickup in Q4, strategic partnerships, and global market expansion.

West Pharmaceutical Services reports solid Q3 performance and eyes growth through automation and strategic investments

West Pharmaceutical Services delivered solid Q3 performance with growth in net sales and adjusted EPS, despite challenges in inventory management and capacity constraints.
The company's strategic investments in automation and capacity expansions position it well for future growth opportunities in HVP and biologics.
While facing industry challenges and uncertainties, West remains confident in meeting or exceeding its growth targets for 2024 through continuous monitoring and adjustment.
Maintaining a strong focus on customer commitments and market differentiation, West Pharmaceutical Services aims to drive growth through innovation and operational efficiency.

West Pharmaceutical Services reports solid Q4 results amidst 2024 challenges

West Pharmaceutical Services navigated challenges in Q4 2023 with solid performance and a focus on growth drivers for 2025, despite anticipated hurdles in 2024.
The company's strategic approach to capital allocation, market share strength, and product focus position it well for future growth and resilience.
Balancing challenges with opportunities, West Pharmaceutical Services aims to sustain growth momentum, overcome obstacles, and drive efficiency and innovation.
With a strong order book outlook, normalized margin rates, and a focus on market trends, West Pharmaceutical Services is poised for continued success and market leadership.

West Pharmaceutical Services navigates mixed Q1 performance with strategic resilience

West Pharmaceutical Services faced challenges in Q1 2024 but demonstrated strengths in strategic planning and resilience.
The company's focus on capacity expansions and maintaining guidance reflects a commitment to long-term growth.
Addressing challenges related to customer destocking and financial performance will be crucial for seizing opportunities and enhancing competitiveness.

West Pharmaceutical Services faces Q2 challenges but eyes future growth

West Pharmaceutical Services navigated challenges in Q2 2024 due to customer destocking, impacting organic sales and gross profit margin. Despite this, management remains optimistic about future growth prospects, aiming to return to a 7% to 9% growth construct. Adjusted full-year guidance reflects a more gradual recovery, with a focus on strategic investments for future growth.

West Pharmaceutical Services reports solid Q3 results amid margin challenges

West Pharmaceutical Services reported solid Q3 performance but faced declines in key financial metrics compared to the previous year. The company is focusing on leveraging its strengths in biologics and expertise to drive future growth, while addressing challenges in margins and organic sales. Opportunities lie in improving performance in Q4 and capitalizing on increased guidance for net sales and adjusted EPS.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

EXTON, Pa., Oct. 8, 2020 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release third-quarter 2020 financial results before the market opens on Thursday, October 22,...

West to Host Third-Quarter 2020 Conference Call

Gilead Sciences

First Trust NYSE Arca Biotechnology Index Fund

Amplify Treatments Testing & Advancements ETF

Pfizer

Regeneron Pharmaceuticals

As the race to develop a vaccine continues, these biotech stocks could be high risk, high return propositions. The post 7 Biotech Stocks To Buy For Profit From The Vaccine Crunch appeared first on InvestorPlace.

7 Biotech Stocks To Buy For Profit From The Vaccine Crunch

Advanced Micro Devices

Amazon

Carrier Global

DexCom

FedEx

Landbridge Co LLC

ServiceNow

NVIDIA

PayPal

The S&P 500 index is up slightly less than 2% this year, after a spring collapse and remarkable rebound.

These Are the 10 Best-Performing Stocks of 2020

Is  (WST) Outperforming Other Medical Stocks This Year?

Is West Pharmaceutical Services (WST) Stock Outpacing Its Medical Peers This Year?

Fiverr

Overstock.com

Trupanion

Wayfair

Here are the best stocks to buy to profit from 2020's biggest trends, such as online retail disruption and an invigorated pet care industry.ce.

7 Best-Performing Stocks to Buy In 4 ProShares ETFs

The stock price of West Pharmaceutical Services, best known for injectable pharmaceutical packaging and delivery systems, has seen a 3x growth since the end of 2017. But how did the company pull off such impressive gains, as its revenues grew just 15% between 2017 and 2019?

Why West Pharmaceutical Services Stock Rallied 3x While Revenues Grew Just 15%?

Sorrento Therapeutics Inc

Coronavirus vaccines get all the attention, but these four pharmaceutical stocks benefit from equipment, drug and test kit developments.
The post 4 Pharmaceutical Stocks With Deep Pipelines appeared first on InvestorPlace.

4 Pharmaceutical Stocks With Deep Pipelines

American States Water

D.R. Horton

Kinsale Capital Group

Gibraltar Industries

As the global economy is still topsy turvy, thanks to the coronavirus pandemic, investors should be even more careful while choosing stocks

Buy These 5 Low Leverage Stocks Amid Ongoing Economic Crisis

ABIOMED

IDEXX Laboratories

Some of the names on this list may surprise you.

These 5 Stocks Are The Biggest S&P 500 Healthcare Winners of 2020

Bio-Rad Laboratories

Danaher

Hologic

Thermo Fisher Scientific

Vertex Pharmaceuticals

Savvy investors should consider adding these stocks to their portfolio to enhance its performance and diversity.

These 10 Stocks Are the Biggest S&P 500 Healthcare Winners of 2020

Descartes Systems Group

Gaia

With the Q2 reporting cycle drawing to a close, investors must be eyeing stocks that exhibited solid earnings growth in the prior quarters. But choosing stocks with high debt level might be risky.

Buy These 5 Low Leverage Stocks to Weather Coronavirus Impact

West Pharmaceutical (WST) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.

Surging Earnings Estimates Signal Good News for West Pharmaceutical (WST)

Lakeland Industries

Medpace Holdings

Piedmont Office Realty Trust

Debt is something that gives you the chills since it brings with it the burden of repayment with additional interest in the future. So investors should choose stocks prudently

Bet on These 5 Low Leverage Stocks This Earnings Season

PulteGroup

PerkinElmer

QuidelOrtho Corp

A new bull market that was developed last quarter exiting the coronavirus-induced short bear market, is raging forward in the third quarter too.

Wall Street is Northbound Defying All Concerns: 5 Top Picks

As of late, it has definitely been a great time to be an investor in West Pharmaceutical Services.

West Pharmaceutical's Shares March Higher, Can It Continue?

West Pharmaceutical Services, Inc. (WST) CEO Eric Green on Q2 2020 Results - Earnings Call Transcript

Shares of West Pharmaceutical Services (NYSE:WST) were flat in pre-market trading after the company reported Q2 results.

West Pharmaceutical Services: Q2 Earnings Insights

EXTON, Pa., July 23, 2020 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the second-quarter 2020 and updated full-year 2020 financial guidance.

West Announces Second-Quarter 2020 Results

West Pharmaceutical (WST) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why West Pharmaceutical (WST) Could Beat Earnings Estimates Again

Boise Cascade

FormFactor

NextEra Energy

To safeguard one's portfolio from notable losses, the real challenge for an investor is determining whether the organization's debt level is sustainable.

5 Low Leverage Stocks to Secure Your Portfolio in 2H2020

Patterson Companies

ResMed

Backed by an upward trend of share prices and projections of robust earnings growth rates, there are a few MedTech stocks which are ideal for long-term bet.

3 Large-Cap MedTech Stocks to Buy on Northbound Market Trend

West Pharmaceutical (WST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: West Pharmaceutical Services (WST) Q2 Earnings Expected to Decline

After a 80% rise since the March 23 lows of this year, at the current price of around $233 per share we believe West Pharmaceutical Services, best known for injectable pharmaceutical packaging and delivery systems, is fully valued based on its historic P/E multiples.

After An 80% Rally, Time To Book Profits In West Pharmaceutical Stock?

AmerisourceBergen

ABC vs. WST: Which Stock Is the Better Value Option?

EXTON, Pa., July 15, 2020 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, announced today that the Company's Board of Directors has approved a third-quarter 2020 dividend of $0.16 per share. The...

News for West Pharmaceutical Services Stock (WST)